Kevin B. Jones

This study identifies TRIM11 as a regulator of EWSR1::ATF1 stability in clear cell sarcoma, showing its depletion leads to metabolic rewiring and cell death, with PCK1 as a potential biomarker.

This study shows that SS18::SSX can drive transcription independently of BAF complex interaction and relies on EP300 for gene activation, suggesting new therapeutic targets for synovial sarcoma.

This study identifies the cell-of-origin of synovial sarcoma as a rare fibroblastic population and shows that SS18::SSX induces an embryonic-like mesenchymal stem cell phenotype.

This study shows that inhibiting SUMOylation with TAK-981 stabilizes cBAF complexes and disrupts the SS18::SSX-driven transcriptome in synovial sarcoma, leading to tumor inhibition.

This paper develops a mouse model for high-risk sarcoma by delivering genetic lesions via electroporation, generating multiple sarcoma types and validating their molecular and therapeutic relevance.

This study examines the epigenomic states of synovial sarcoma using multi-omics analysis, revealing a continuum of epigenomic states and identifying H3K4me3 inhibition as a potential therapeutic strategy.

This paper shows SS18::SSX fusion protein alters BAF chromatin remodeler distribution, leading to transcriptional activation and repression by changing histone modifications at regulatory regions.

This study identifies VCP/p97 as an obligate co-factor of ASPSCR1-TFE3, showing it organizes enhancer loops to drive oncogenic transcription in ASPS and RCC.